Speed, Scrutiny, and Spending: How Washington Is Reshaping the Future of Medicine

Washington is navigating a period of significant change in health policy, with implications for how new medicines are developed, reviewed, and paid for.In this episode of Making Medicine, we take a closer look at several recent developments shaping the life sciences landscape. We discuss the FDA’s new priority review voucher pilot and the debate around how the agency can balance speed, scientific rigor, and public trust as it works to accelerate patient access to therapies.We also break down new reforms aimed at increasing transparency in Medicare Part D and reining in pharmacy benefit manager (PBM) practices, exploring what these changes could mean for patients, payers, and innovators across the system.Finally, we examine emerging international reference pricing proposals, including the GLOBE and GUARD concepts, and the broader conversation about how the U.S. can maintain its leadership in biomedical innovation while addressing affordability and global competition. If you care about the future of medical innovation, and the policy decisions shaping it, this episode offers context, clarity, and a balanced look at what’s ahead.Link to article: https://www.washingtonpost.com/opinions/2026/02/03/vaccine-development-moderna-rfk-china-drug-prices/Join the Conversation ⬇️Do you believe the government has become the biggest obstacle to the next American cure? Will the U.S. lose its status as the world leader in medical breakthroughs by 2030? Is the FDA's new 'National Priority' pilot a necessary evolution for 21st-century medicine, or is it a dangerous bypass of the scientific checks and balances that protect us all?Drop your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps0:00  The 1,000-pound predator and the regulatory coup0:23  Science, policy, and a destabilized ecosystem1:10  The controversial FDA town hall2:20  Skipping Congressional approval3:54  Reforming PBMs in the funding package5:10  How PBMs siphon half the cost of your medicine6:55  Why "sunlight" isn't lowering pharmacy prices yet7:54  GLOBE, GUARD, and foreign price controls8:32  Why biotech is fleeing to rival markets9:30  Shifting from price controls to insurance reform10:12  Addressing out-of-pocket costs 10:45  FDA Approvals CornerDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.